| Attribute |
Value |
| 52 Week Change |
-0.8552381 |
| Address1 |
5,300 Memorial Drive |
| Address2 |
Suite 950 |
| All Time High |
21,555.0 |
| All Time Low |
1.79 |
| Ask |
2.81 |
| Ask Size |
2 |
| Average Analyst Rating |
1.3 - Strong Buy |
| Average Daily Volume10 Day |
821,660 |
| Average Daily Volume3 Month |
520,416 |
| Average Volume |
520,416 |
| Average Volume10Days |
821,660 |
| Beta |
1.751 |
| Bid |
1.62 |
| Bid Size |
2 |
| Book Value |
2.845 |
| City |
Houston |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.21 |
| Current Ratio |
1.377 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
2.29 |
| Day Low |
2.18 |
| Debt To Equity |
2.147 |
| Display Name |
Moleculin Biotech |
| Dividend Date |
1,612,137,600 |
| Earnings Call Timestamp End |
1,747,225,800 |
| Earnings Call Timestamp Start |
1,747,225,800 |
| Earnings Timestamp End |
1,754,656,200 |
| Earnings Timestamp Start |
1,754,310,600 |
| Ebitda |
-26,967,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-0.067 |
| Enterprise Value |
1,802,333 |
| Eps Current Year |
-121.25 |
| Eps Forward |
-110.5 |
| Eps Trailing Twelve Months |
-15.66 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
2.5666 |
| Fifty Day Average Change |
-0.35660005 |
| Fifty Day Average Change Percent |
-0.13893868 |
| Fifty Two Week Change Percent |
-85.52381 |
| Fifty Two Week High |
24.0 |
| Fifty Two Week High Change |
-21.79 |
| Fifty Two Week High Change Percent |
-0.9079167 |
| Fifty Two Week Low |
1.79 |
| Fifty Two Week Low Change |
0.42000008 |
| Fifty Two Week Low Change Percent |
0.23463692 |
| Fifty Two Week Range |
1.79 - 24.0 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,464,874,200,000 |
| Float Shares |
5,291,311 |
| Forward Eps |
-110.5 |
| Forward P E |
-0.02 |
| Free Cashflow |
-13,153,250 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
17 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00629 |
| Held Percent Institutions |
0.03326 |
| Implied Shares Outstanding |
7,065,000 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,764,547,200 |
| Last Split Factor |
1:25 |
| Long Business Summary |
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas. |
| Long Name |
Moleculin Biotech, Inc. |
| Market |
us_market |
| Market Cap |
15,613,650 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_320105606 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-42,370,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
15,613,650 |
| Number Of Analyst Opinions |
3 |
| Open |
2.25 |
| Operating Cashflow |
-24,282,000 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
713 300 5160 |
| Pre Market Change |
0.0 |
| Pre Market Change Percent |
0.0 |
| Pre Market Price |
2.21 |
| Pre Market Time |
1,784,016,023 |
| Previous Close |
2.28 |
| Price Eps Current Year |
-0.018226804 |
| Price Hint |
4 |
| Price To Book |
0.7768014 |
| Profit Margins |
0.0 |
| Quick Ratio |
1.297 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.33333 |
| Region |
US |
| Regular Market Change |
-0.0699999 |
| Regular Market Change Percent |
-3.07017 |
| Regular Market Day High |
2.29 |
| Regular Market Day Low |
2.18 |
| Regular Market Day Range |
2.18 - 2.29 |
| Regular Market Open |
2.25 |
| Regular Market Previous Close |
2.28 |
| Regular Market Price |
2.21 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
117,135 |
| Return On Assets |
-0.7615 |
| Return On Equity |
-5.32033 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
7,065,000 |
| Shares Percent Shares Out |
0.2001 |
| Shares Short |
1,413,550 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
828,958 |
| Short Name |
Moleculin Biotech, Inc. |
| Short Percent Of Float |
0.2014 |
| Short Ratio |
1.31 |
| Source Interval |
15 |
| State |
TX |
| Symbol |
MBRX |
| Target High Price |
31.0 |
| Target Low Price |
10.0 |
| Target Mean Price |
21.0 |
| Target Median Price |
22.0 |
| Total Cash |
10,317,000 |
| Total Cash Per Share |
1.933 |
| Total Debt |
326,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-15.66 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
5.218655 |
| Two Hundred Day Average Change |
-3.008655 |
| Two Hundred Day Average Change Percent |
-0.57651925 |
| Type Disp |
Equity |
| Volume |
117,135 |
| Website |
https://moleculin.com |
| Zip |
77,007 |